Type:Injection
Generic Name:Dobutamine
Manufacturer:Incepta Pharmaceuticals Ltd.
Price:৳250.00
Heart failure, Cardiac stress test
IV Preparation Solution: Dilute 250 mg in 250 mL of compatible solution to yield final concentration of 1000 mcg/mL; not to exceed 5000 mcg/mL The rate of administration and the duration of therapy should be adjusted according to the patient's response, The indicators are: haemodynamic parameters such as heart rate and rhythm, arterial pressure, and, whenever possible, cardiac output and measurements of ventricular filling pressures and signs of pulmonary congestion. Because of its short half-life, Dobutamine Hydrochloride must be administered as a continuous intravenous infusion. Following the initiation of a constant rate infusion, or upon changing the rate, a steady-state dobutamine plasma concentration is achieved within approximately 10 minutes. Thus, loading doses or bolus injections are not necessary and are not recommended.
Cardiac Decompensation 0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min Adjust according to patient's BP, heart rate, cardiac and urine output.
Cardiac Decompensation 0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min
Hypersensitivity; idiopathic hypertrophic subaortic stenosis (IHSS).
Dobutamine increases contractility and heart rate by stimulating ?-adrenergic receptors in the cardiac tissues.
Correct hypovolaemia prior to treatment. Increased risk of rapid ventricular response in patients with atrial fibrillation. Insufficient data to determine the safety and efficacy of dobutamine use after acute MI. Elderly. Neonates. Pregnancy. Lactation: Unknown whether drug is excreted into breast milk; avoid use
1-10% Tachyarrhythmia (10%),Hypertension (7.5%),Eosinophilic myocarditis (<7%),Premature ventricular beats (5%; dose related),Angina (1-3%),Dyspnea (1-3%),Fever (1-3%),Headache (1-3%),Nausea (1-3%),Palpation (1-3%) Frequency Not Defined Cardiac dysrhythmia,Exacerbation of coronary arteriosclerosis,Hypokalemia,Injection-site reactions,Syncope,10- to 20-mm Hg increase in systolic blood pressure and increase in heart rate of 5 to 15 beats/min Potentially Fatal: Cardiac arrhythmias, allergy (rare), MI and hypotension.
Pregnancy category: B Lactation: Unknown whether drug is excreted into breast milk; avoid use
Increased cardiac output when used with nitroprusside. Increased vasopressor effect of dobutamine when used with bretylium, guanethidine, oxytocic drugs or TCAs.
